Investor Update
Basel, 3 July 2006
FDA
approves Lucentis for the treatment of wet age-related macular degeneration
Genentech
news release announcing that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab
injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD).